Seroprevalence of anti-SARS-CoV-2 antibody in response to COVID-19 vaccine in patients with i nflammatory bowel disease SARS-CoV-2

Keimyung University Dongsan Hospital0 个研究点目标入组 150 人开始时间: 待定最近更新: 2022年1月11日

试验速览

暂无简介。

•1. Patients who are scheduled to receive SARS-CoV-2 vaccine (BNT162b2, mRNA-1273) among IBD patients aged 20 to 80 years
•2. Patients who are expected to complete SARS-CoV-2 vaccination among IBD patients aged 20 to 80 years
•3. A person who has signed a written consent form after agreeing to the purpose and method of the clinical research
•4. Patients taking 5-aminosalicylic acid (ASA), immunomodulatory agents, or biological agents (infliximab or vedolizumab) among Crohn's disease/ulcerative colitis patients

•1. Patients with IBD for whom information on adverse reactions related to vaccination cannot be obtained
•2. Patients with acute illness who have been hospitalized within 4 weeks of starting vaccination
•3. Patients who have had surgery within 3 months
•4. Those who have passed more than 19 weeks after completing the second dose of vaccine
•5. Subjects who do not agree to participate in the study

发起方

Keimyung University Dongsan Hospital